Tribunal Decision: Disallowance of Fees Upheld, Expenses Set Aside, Revenue's Appeal Dismissed

The Tribunal partly allowed the assessee's appeal by upholding the disallowance related to fees paid to Medunet Europe B.V., setting aside the disallowance related to expenses paid to Pfizer Corporation Hong Kong Limited, and restoring the issue of scholarship fees for further examination. The Revenue's appeal was dismissed as the Tribunal upheld the deletion of the disallowance of cross charges paid to M/s. Pfizer Ltd., emphasizing that reimbursements without profit elements do not attract tax deduction at source.

---

---

Issues Involved:
1. Disallowance under section 40(a)(i) of the Income Tax Act for fees paid to Medunet Europe B.V.
2. Disallowance under section 40(a)(i) of the Income Tax Act for reimbursement of expenses paid to Pfizer Corporation Hong Kong Limited.
3. Disallowance under section 40(a)(i) of the Income Tax Act for scholarship fees paid to a doctor.
4. Deletion of disallowance of cross charges paid to M/s. Pfizer Ltd. for non-deduction of TDS.

Detailed Analysis:

1. Disallowance under section 40(a)(i) for fees paid to Medunet Europe B.V.:
The first issue pertains to the disallowance of Rs. 50,553 paid to Medunet Europe B.V. for technical services towards copyright and printable files. The Assessing Officer (AO) and the Commissioner of Income-tax (Appeals) [CIT(A)] disallowed the expenditure under section 40(a)(i) due to the assessee's failure to deduct the requisite tax at source. The Tribunal affirmed the orders of the lower authorities, noting that the assessee did not provide any credible explanation for not deducting tax on the payment. Therefore, the disallowance was upheld.

2. Disallowance under section 40(a)(i) for reimbursement of expenses paid to Pfizer Corporation Hong Kong Limited:
The second issue concerns the disallowance of Rs. 13,67,801 paid to Pfizer Corporation Hong Kong Limited, which the assessee claimed were reimbursements of expenses. The AO disallowed the expenditure under section 40(a)(i) for non-deduction of tax at source. The CIT(A) upheld the disallowance, stating that the assessee did not furnish details to substantiate that the payments were merely reimbursements. However, the Tribunal found that there was sufficient material on record, including detailed invoices, to support the assessee's claim that the payments were reimbursements. Consequently, the Tribunal set aside the disallowance, holding that there was no requirement to deduct tax at source on mere reimbursements.

3. Disallowance under section 40(a)(i) for scholarship fees paid to a doctor:
The third issue involves the disallowance of Rs. 1,90,315 paid as scholarship fees to a doctor. The AO disallowed the expenditure under section 40(a)(i) for non-deduction of tax at source. The assessee argued that the amount was not taxable in India due to Article 7 of the Double Taxation Avoidance Agreement, as the recipient did not have a Permanent Establishment in India. The CIT(A) did not adjudicate this ground. The Tribunal restored the matter to the file of the CIT(A) for examination and adjudication, allowing the assessee's appeal for statistical purposes.

4. Deletion of disallowance of cross charges paid to M/s. Pfizer Ltd. for non-deduction of TDS:
The Revenue's appeal focused on the deletion of the disallowance of Rs. 14,51,77,000 paid to M/s. Pfizer Ltd. The AO disallowed the expenditure under section 40(a)(ia) for non-deduction of tax at source, arguing that the payments included a profit component and were not mere reimbursements. The CIT(A) disagreed, concluding that the payments were reimbursements without any mark-up, supported by a cost-sharing agreement and confirmations from M/s. Pfizer Ltd. The Tribunal upheld the CIT(A)'s decision, noting that reimbursements without profit elements do not attract TDS. Additionally, the Tribunal observed that the CIT(A) correctly applied the second proviso to section 40(a)(ia) and section 201(1) of the Act, which exempts the assessee from being treated as in default if the payee has complied with tax obligations. The Tribunal found no reason to interfere with the CIT(A)'s decision and dismissed the Revenue's appeal.

Conclusion:
- The appeal of the assessee was partly allowed, with the Tribunal upholding the disallowance related to Medunet Europe B.V., setting aside the disallowance related to Pfizer Corporation Hong Kong Limited, and restoring the issue of scholarship fees to the CIT(A).
- The Revenue's appeal was dismissed, with the Tribunal upholding the CIT(A)'s deletion of the disallowance related to cross charges paid to M/s. Pfizer Ltd.

---